Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma
Clinical trial NCT00322608 · COMPLETED
Trial details
- NCT number
- NCT00322608
- Sponsor
- Nereus Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2006-04-01
- Primary completion
- 2009-09-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.